|

A Study of EOC237 in Patients With Advanced Solid Tumor

RECRUITINGPhase 1Sponsored by Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd
Actively Recruiting
PhasePhase 1
SponsorShanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd
Started2023-07-26
Est. completion2026-04-30
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05895825

Summary

This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Advanced Solid Tumors for which standard curative or palliative measures do not exist or are no longer effective.
* Expected survival≥ 3 months.
* ECOG performance status 0-1.
* Good organ and marrow function.

Exclusion Criteria:

* Patients with a history of severe drug allergic reaction.
* Pregnant or lactating female subjects.
* Uncontrolled, significant intercurrent or recent illness.
* Corrected QT interval calculated by the Fridericia formula (QTcF) \> 480 ms per electrocardiogram (ECG)
* Concomitant use of certain medications

Conditions2

Advanced Solid TumorCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.